

BIOTECHNOLOGY FUND

| | SHARES | VALUE | | SHARES | VALUE |
|--|------------|--------------------|---------------|--------|-----------------------|
| COMMON STOCKS[†] - 99.6% | | | | | |
| BIOTECHNOLOGY - 75.7% | | | | | |
| Amgen, Inc. | 50,484 | \$ 12,831,013 | | | |
| Gilead Sciences, Inc. | 145,017 | 9,163,624 | | | |
| Vertex Pharmaceuticals, Inc.* | 31,980 | 8,702,398 | | | |
| Regeneron Pharmaceuticals, Inc.* | 14,326 | 8,019,408 | | | |
| Illumina, Inc.* | 23,943 | 7,400,302 | | | |
| Biogen, Inc.* | 24,970 | 7,083,490 | | | |
| Seattle Genetics, Inc.* | 32,819 | 6,422,350 | | | |
| Moderna, Inc.* ¹ | 79,814 | 5,646,841 | | | |
| Alexion Pharmaceuticals, Inc.* | 46,050 | 5,269,502 | | | |
| Exact Sciences Corp.* | 46,904 | 4,781,863 | | | |
| Corteva, Inc. | 164,401 | 4,736,393 | | | |
| Immunomedics, Inc.* | 54,114 | 4,601,313 | | | |
| Incyte Corp.* | 50,994 | 4,576,202 | | | |
| Alnylam Pharmaceuticals, Inc.* | 30,948 | 4,506,029 | | | |
| BioMarin Pharmaceutical, Inc.* | 49,129 | 3,737,734 | | | |
| Guardant Health, Inc.* | 33,016 | 3,690,528 | | | |
| Mirati Therapeutics, Inc.* | 17,263 | 2,866,521 | | | |
| Accelaron Pharma, Inc.* | 24,562 | 2,763,962 | | | |
| Exelixis, Inc.* | 110,704 | 2,706,713 | | | |
| ACADIA Pharmaceuticals, Inc.* | 63,663 | 2,626,099 | | | |
| Ionis Pharmaceuticals, Inc.* | 54,519 | 2,586,927 | | | |
| Ultragenyx Pharmaceutical, Inc.* | 28,179 | 2,316,032 | | | |
| Iovance Biotherapeutics, Inc.* | 67,234 | 2,213,343 | | | |
| Arrowhead Pharmaceuticals, Inc.* | 50,057 | 2,155,454 | | | |
| United Therapeutics Corp.* | 21,148 | 2,135,948 | | | |
| FibroGen, Inc.* | 47,812 | 1,966,029 | | | |
| Bluebird Bio, Inc.* | 35,365 | 1,907,942 | | | |
| PTC Therapeutics, Inc.* | 38,968 | 1,821,754 | | | |
| BeiGene Ltd. ADR* | 5,800 | 1,661,352 | | | |
| Nektar Therapeutics* | 97,423 | 1,616,248 | | | |
| Inovio Pharmaceuticals, Inc.* ¹ | 116,860 | 1,355,576 | | | |
| Ligand Pharmaceuticals, Inc. — Class B* ¹ | 13,671 | 1,303,120 | | | |
| Sage Therapeutics, Inc.* | 20,116 | 1,229,490 | | | |
| Intercept Pharmaceuticals, Inc.* | 28,763 | 1,192,514 | | | |
| Myriad Genetics, Inc.* | 81,833 | 1,067,102 | | | |
| Total Biotechnology | | <u>138,661,116</u> | | | |
| PHARMACEUTICALS - 19.7% | | | | | |
| AbbVie, Inc. | 146,002 | 12,788,315 | | | |
| Horizon Therapeutics plc* | 55,205 | 4,288,324 | | | |
| Sarepta Therapeutics, Inc.* | 24,269 | 3,408,096 | | | |
| Neurocrine Biosciences, Inc.* | 31,356 | 3,015,193 | | | |
| Mylan N.V.* | 185,027 | 2,743,951 | | | |
| PRA Health Sciences, Inc.* | 25,975 | 2,634,904 | | | |
| Jazz Pharmaceuticals plc* | 15,387 | 2,194,032 | | | |
| Global Blood Therapeutics, Inc.* | 34,855 | 1,921,905 | | | |
| Agios Pharmaceuticals, Inc.* | 43,800 | 1,533,000 | | | |
| Alkermes plc* | 88,567 | 1,467,555 | | | |
| Total Pharmaceuticals | | <u>35,995,275</u> | | | |
| HEALTHCARE-PRODUCTS - 2.9% | | | | | |
| Bio-Techne Corp. | 13,008 | \$ 3,222,472 | | | |
| Novocure Ltd.* | 18,563 | 2,066,247 | | | |
| Total Healthcare-Products | | <u>5,288,719</u> | | | |
| HEALTHCARE-SERVICES - 1.3% | | | | | |
| Syneos Health, Inc.* | 45,520 | 2,419,843 | | | |
| Total Common Stocks | | | | | |
| (Cost \$80,357,956) | | | | | <u>182,364,953</u> |
| RIGHTS^{†††} - 0.0% | | | | | |
| BIOTECHNOLOGY - 0.0% | | | | | |
| Clinical Data, Inc.* | 24,000 | — | | | |
| Total Rights | | | | | <u>—</u> |
| (Cost \$—) | | | | | <u>—</u> |
| | | | FACE | | |
| | | | AMOUNT | | |
| | | | | | |
| REPURCHASE AGREEMENTS^{††2} - 0.7% | | | | | |
| J.P. Morgan Securities LLC | | | | | |
| issued 09/30/20 at 0.06% | | | | | |
| due 10/01/20 | \$ 762,778 | 762,778 | | | |
| BofA Securities, Inc. | | | | | |
| issued 09/30/20 at 0.06% | | | | | |
| due 10/01/20 | 317,490 | 317,490 | | | |
| Barclays Capital, Inc. | | | | | |
| issued 09/30/20 at 0.06% | | | | | |
| due 10/01/20 | 288,915 | 288,915 | | | |
| Total Repurchase Agreements | | | | | <u>1,369,183</u> |
| (Cost \$1,369,183) | | | | | |
| | | | SHARES | | |
| | | | | | |
| SECURITIES LENDING COLLATERAL^{†3} - 3.1% | | | | | |
| Money Market Fund | | | | | |
| First American Government | | | | | |
| Obligations Fund — Class Z, 0.05% ⁴ | 5,605,263 | 5,605,263 | | | |
| Total Securities Lending Collateral | | | | | <u>5,605,263</u> |
| (Cost \$5,605,263) | | | | | |
| Total Investments - 103.4% | | | | | <u>\$ 189,339,399</u> |
| (Cost \$87,332,402) | | | | | |
| Other Assets & Liabilities, net - (3.4)% | | | | | <u>(6,165,567)</u> |
| Total Net Assets - 100.0% | | | | | <u>\$ 183,173,832</u> |

BIOTECHNOLOGY FUND

- * Non-income producing security.
 - † Value determined based on Level 1 inputs.
 - †† Value determined based on Level 2 inputs.
 - ††† Value determined based on Level 3 inputs.
 - ¹ All or a portion of this security is on loan at September 30, 2020.
 - ² Repurchase Agreements.
 - ³ Securities lending collateral.
 - ⁴ Rate indicated is the 7-day yield as of September 30, 2020.
- ADR — American Depositary Receipt
plc — Public Limited Company